Reaction

Macular Oedema reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,524 reports · 81 co-occurring drugs

As of the last recalculation, Macular Oedema appears in 5,524 FAERS reports alongside 81 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 91.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranibizumab	578	91.5	93.5
Fingolimod Hcl	863	44.4	44.8
Aflibercept	258	32.6	32.9
Siponimod	68	29.1	29.3
Cefuroxime	74	24.7	24.9
Encorafenib	49	18.8	18.9
Brinzolamide	33	14.4	14.4
Prednisolone Acetate	39	14.3	14.3
Dorzolamide Hydrochloride And Timolol Maleate	28	13.4	13.5
Ozanimod Hydrochloride	29	13.2	13.3
Ganciclovir Sodium	34	12.2	12.2
Faricimab	26	12.1	12.2
Adalimumab-Fkjp	142	11.8	11.9
Brimonidine Tartrate	55	11.7	11.8
Adalimumab-Aaty	142	11.6	11.6
Ganciclovir	30	11.1	11.1
Adalimumab-Adaz	149	10.9	10.9
Bevacizumab	331	10.6	10.7
Travoprost	23	10.1	10.1
Cefazolin	22	9.1	9.1
Pioglitazone	95	8.4	8.4
Insulin Glulisine	22	8.2	8.2
Cefazolin Sodium	25	7.8	7.9
Timolol	24	7.5	7.5
Moxifloxacin Hydrochloride	38	7.1	7.1
Paclitaxel	180	7.0	7.1
Triamcinolone Acetonide Ointment Usp, 0.05%	41	6.6	6.6
Triamcinolone Acetonide	53	6.5	6.5
Latanoprost	73	5.5	5.5
Bimatoprost	40	5.3	5.3
Vemurafenib	16	5.0	5.0
Glyburide	32	5.0	5.0
Insulin	73	5.0	5.0
Dabrafenib	27	4.8	4.9
Quinine	11	4.8	4.8
Trametinib	29	4.5	4.5
Amlodipine Besylate And Valsartan	12	4.1	4.1
Insulin Human	39	3.7	3.7
Human Insulin	12	3.6	3.6
Cetuximab	30	3.6	3.6
Raloxifene Hydrochloride	14	3.6	3.6
Moxifloxacin	13	3.5	3.5
Timolol Maleate	9	3.4	3.4
Paclitaxel (Aibumin-Bound)	73	3.4	3.4
Metformin Hcl	49	3.4	3.4
Dexamethasone Sodium Phosphate	9	3.3	3.3
Tobramycin	21	3.3	3.3
Gemcitabine Hydrochloride	46	3.3	3.3
Modafinil	28	3.3	3.3
Tobramycin Sulfate	10	3.0	3.0
Ezetimibe And Simvastatin	12	3.0	3.0
Nevirapine	7	2.9	2.9
Insulin Degludec	18	2.9	2.9
Tobramycin Solution	9	2.8	2.8
Lubiprostone	7	2.8	2.8
Glipizide	44	2.7	2.7
Amantadine	11	2.7	2.7
Insulin Aspart	45	2.6	2.6
Sumatriptan Succinate	16	2.4	2.4
Efavirenz	7	2.4	2.4
Pertuzumab	14	1.9	1.9
Insulin Glargine	124	1.9	1.9
Trastuzumab	34	1.9	1.9
Dexamethasone	144	1.9	1.9
Oral Semaglutide	35	1.8	1.8
Dimethyl Fumarate	58	1.8	1.8
Teriflunomide	21	1.8	1.8
Insulin Lispro	62	1.7	1.7
Gefitinib	4	1.7	1.7
Romiplostim	6	1.5	1.5
Docetaxel Anhydrous	26	1.5	1.5
Docetaxel	26	1.5	1.5
Exenatide	20	1.4	1.4
Glatiramer Acetate	21	1.3	1.3
Cortisone Acetate	4	1.2	1.2
Ipilimumab	13	1.1	1.1
Ofatumumab	10	1.1	1.1
Dalfampridine	21	1.1	1.1
Alirocumab	6	0.9	0.9
Dulaglutide	21	0.9	0.9
Tirzepatide	24	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.